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Cytotoxic T cells transduced with chimeric anti-CD19 receptors 
prevent engraftment of primary lymphoblastic leukemia in vivo 
Letter to the Editor 
Despite considerable advances in the treatment of B-cell precursor acute lymphoblastic 
leukemia (BCP-ALL), 10-20% of children and >60% of adults still fail available therapies(1). 
Hematopoietic stem cell transplantation (HSCT) has contributed to favorable outcomes in 
high-risk or recurrent ALL in both pediatric and adult populations, however, overt relapses 
after transplant are currently incurable. Patients at high risk for a subsequent relapse can 
now be identified by quantification of minimal residual disease (MRD) before 
transplantation(2), facilitating assessment of novel strategies to maintain remission and 
improve prognosis. Adoptive transfer of cytotoxic T cells (CTLs) is one means to enhance 
the therapeutic potential of HSCT. While alloreactive donor lymphocytes can exert potent 
effects against myeloid leukemias(3), attempts to exploit unmanipulated donor T cells for the 
treatment of high-risk ALL have had limited success(3), indicating the lack of immunogenic 
targets for graft-versus-leukemia responses in this malignancy.  
One alternative to harness the cytotoxic potential of T cells is to redirect their specificity to 
leukemia cells by genetic engineering with chimeric antigen-specific receptors (CARs). CARs 
consist of an antibody-derived recognition domain, linked to signaling molecules that activate 
T cells upon interaction with cells expressing the respective target antigen on their 
surface(4). CD19 is an attractive target for immunological therapies in BCP-ALL because it is 
expressed at high densities on most malignant B cells and expression is restricted to the B-
cell lineage. CARs against CD19 have now been generated by various groups and have 
been demonstrated to mediate potent T-cell effector functions against CD19-expressing 
malignant cells in vitro and in vivo(5). Specifically, human T cells endowed with CD19-
specific CARs have been shown to effectively eradicate human CD19+ tumor xenografts in 
immuno-deficient mouse models(5). So far, in vivo evidence for the antileukemia activity of 
CD19-specific T cells has been restricted to established tumor cell lines. Primary leukemia 
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cells more closely mimic the heterogeneity of the disease in humans and allow to 
differentiate between individual subgroups with variable biological risk profiles. In this study, 
we have investigated the in vivo sensitivity of human leukemic bone marrow (BM) to adoptive 
immunotherapy with gene-modified CD19-specific T cells.  
Unmanipulated BM cells (3-8x106 per mice) from pediatric patients at first diagnosis of BCP-
ALL were transplanted via intrafemoral injection into 8 to 12 week old NOD/scid mice 
(Charles River Laboratories, Sulzfeld, Germany) without pre-transplant conditioning, as 
described previously(6). Leukemia engraftment was monitored by serial BM aspirations from 
femoral punctures, followed by assessment and quantification of human leukemia cells by 
flow cytometric analysis of cells within the lymphocyte gate expressing human CD19 and 
CD45. Among primary leukemia samples from 15 individual patients, 10 were successfully 
engrafted in at least 1 NOD/scid mouse within 6 to 20 weeks (supplemental table 1). In all 
mice analyzed, the human cells had a B-cell precursor phenotype consistent with the original 
diagnosis. Engraftment of human cells correlated with the development of splenomegaly, 
indicating that transplanted mice developed overt leukemia. One limitation to using primary 
leukemia samples for therapeutic experiments is the heterogeneous engraftment and 
manifestation of the disease in only a proportion of transplanted mice. To develop a more 
reliable in vivo assay, we performed serial transplantations of the human leukemias into 
secondary recipients. While the time to first detection of human leukemia cells in murine BM 
was not significantly reduced, secondary transplantations ensured subsequent engraftment 
in 4 out of 4 individual primary leukemias. To determine the lowest numbers of primary 
leukemia cells reliably engrafting secondary murine recipients, a series of titration 
experiments were performed. Transplantation of minimal numbers of 1x104 leukemic cells 
resulted in engraftment after 3 weeks (supplemental figure A).  
As effector cells for CD19-directed adoptive therapy, we chose to use CTLs with native 
specificity for Epstein-Barr virus (EBV) antigens since virus-specific donor T cells have a 
number of potential advantages for subsequent clinical application: EBV-CTLs have been 
safely administered to >100 patients to reconstitute EBV-specific immunity after allogeneic 
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HSCT, and they persist and show long-term function without causing graft-versus-host 
disease (GVHD)(7). Moreover, since EBV-CTLs do not require polyclonal stimulation for 
efficient retroviral transduction and may receive potent reactivation stimuli in vivo through 
engagement of the endogenous TCR, they may generate persistent memory responses. 
Indeed, CAR-transduced EBV-CTLs had improved in vivo persistence over polyclonal T cells 
in a recent clinical study(8). As a beneficial side effect, adoptive transfer of donor-derived 
EBV-CTLs will protect the recipient from EBV-associated post-transplant complications. 
EBV-CTLs were expanded from 4 healthy donors by coculture with autologous EBV-
transformed lymphoblastoid cell lines (LCLs)(7;8) and transduced to express a CD19-
specific CAR (CD19ζ). CD19ζ was generated by cloning the variable domains of the heavy 
and light chain of the monoclonal anti-CD19 antibody FMC63 (provided by H. Zola, Adelaide, 
Australia) in frame with a membrane-spanning domain consisting of human immunoglobulin 
constant domains CH2 and CH3, and the transmembrane and cytoplasmic domains of the 
TCR ζ chain. Costimulatory domains found to enhance the systemic antitumor activity of 
non-specifically stimulated, CAR-modified T cells(5) were not included, since previous 
studies have shown that CAR activity in virus-specific CTLs does not benefit from additional 
signaling elements(8). For control experiments, an analogous CAR directed against the 
neuroectodermal antigen GD2 (14.G2aζ) was used(8).  
For gene transfer into CTLs, the CAR transgenes were subcloned into the retroviral vector 
SFG (provided by R.C. Mulligan, Cambridge, MA, USA), and stable retroviral producer cell 
lines were generated by transient production of retrovirus in Phoenix ampho cells (G. P. 
Nolan, Stanford, CA, USA) and subsequent infection of the packaging cell line FLYRD18 (E. 
Vanin, Houston, TX, USA) by overnight incubation at 37°C in the presence of polybrene 
(4µg/ml). Viral supernatants were generated on the resulting bulk producer cell lines by 
adding Iscove´s modified Dulbecco medium (IMDM; BioWhittaker) supplemented with 20% 
FCS, followed by  24 hours of incubation at 32°C. T he resulting viral supernatants were 
filtered (0.45 µm) and used to transduce the EBV-CTLs following their third stimulation with 
autologous LCLs. Transduction efficiencies were assessed by surface staining of transduced 
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EBV-CTLs with a biotinylated goat anti-mouse antibody specific for IgG F(ab’)2 fragment 
(Jackson ImmunoResearch, Cambridgeshire, UK) and secondary phycoerythrin (PE)-labeled 
streptavidin antibody (Becton Dickinson, San Jose, CA, USA) (Figure 1A). CD19ζ surface 
expression in 9 transduced CTL lines was 73±21%, range 32-93%, and 14.G2aζ expression 
in 5 lines was 18±13%, range 6-35%. The T-cell lines had a characteristic CTL phenotype, 
with 95.5±4.9% expressing CD3, of which a mean of 82.3±17.6% coexpressed CD8 (median 
of 89.7%), while 17.7±17.6% (median of 10,3%) had a T helper phenotype (CD3+CD4+). The 
majority of CD8+ T cells expressed CD45RO in the absence of CCR7, corresponding to an 
effector memory T-cell phenotype (Figure 1B). Immunophenotypes were unaffected by CAR 
gene expression. 
In vitro cytotoxicity experiments by 4-hour 51Cr release assays confirmed specific lysis of the 
CD19+ leukemia cell lines REH (51Cr release 59.7±7.2% at an effector target ratio of 20:1) 
(Figure 1C) and SupB15 (66.7±8.6; Figure 1D), in the absence of background lysis by 
14.G2aζ-transduced control CTLs (3.3±3.1% and 4.9±5.0%, respectively) or appreciable 
cytotoxicity against the CD19-negative human acute myelomonocytic leukemia cell line ML-2 
(14.9±1.9%). CAR-transduced CTLs maintained their cytolytic activity against autologous 
EBV targets, and 14.G2aζ transduced EBV targets effectively lysed tumor target cells 
expressing the 14.G2a target antigen GD2 (not shown). To investigate the in vitro sensitivity 
of primary leukemic cells to CD19-redirected T cells, BM leukemia cells obtained at 
diagnosis from five pediatric patients with CD19+ B-cell precursor cell ALL were used as 
targets in further cytotoxicity experiments. Primary leukemic cells from all patients were 
efficiently lysed by allogeneic CD19ζ transduced CTLs but not 14.G2aζ transduced or non-
transduced CTLs from the same donors in vitro (Figure 1D). Functional interaction of CD19ζ 
transduced CTLs with primary leukemic cells in vitro was further confirmed by specific IFN-γ 
secretion in ELISPOT assays (Figure 1E). 
To analyze the in vivo sensitivity of primary human leukemia to adoptive immunotherapy with 
CD19ζ T cells, we focused on a connatal CD19+CD10- leukemia, bearing the high-risk 
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feature of an MLL-ENL rearrangement due to a t(11;19) translocation. The disease was 
refractory to standard treatment and fatal prior to intended allogeneic HSCT. 1x104 BM 
leukemia cells per mouse from one engrafted primary mouse were serially transplanted into 
a further cohort of 13 NOD/scid mice by secondary intrafemoral transplantation, followed by 
adoptive transfer of 4 doses of 5x106 CD19ζ or 14.G2aζ-transduced CTLs via tail vein 
injection on days 1, 4, 8, and 11. IL-2 (500 IU/mouse) was administered twice-weekly. 
Human leukemia engraftment was monitored in both the CD19ζ-treated and the control 
group by flow cytometry analysis of sequential BM aspirates starting 3 weeks after 
transplantation. While the human leukemia became detectable in the BM of 4 of 5 control 
mice, followed by overt and fatal leukemia in all cases, 5 of 8 mice receiving transfusions of 
CD19ζ transduced CTLs remained disease-free (p = 0.07, Log Rank/Mantel-Cox Test), and 
6 of 8 remained alive, one of them with detectable leukemia cells (p = 0.05) (Figure 2). Since 
the natural life-span in this NOD/scid mouse strain is limited by the development of 
spontaneous murine thymomas, retransplantation experiments were performed to extend 
leukemia follow-up. 4x106 BM cells obtained from a CD19ζ-treated mouse were transferred 
intrafemorally to a further cohort of three 10-week old mice. All mice remained leukemia-free 
for a further follow-up of 8-10 weeks. CTLs were detected in peripheral blood for 2 days 
(supplemental figure B). Infusions were well tolerated without any clinical or histological 
signs of toxicity or GVHD. 
Thus, adoptive transfer of CD19-redirected CTLs can efficiently delay or prevent 
engraftment of primary human high risk ALL cells in vivo, encouraging the clinical 
development of this strategy for patients refractory to standard treatment. The data reported 
here for the first time extend previous preclinical in vivo experience with established cell lines 
towards primary human leukemia samples. The attractiveness of this NOD/scid model is 
based on the observation that NOD/scid repopulating human leukemic cells closely resemble 
leukemic stem cells (for further literature see ref. 6) that carry the capacity to self-renew and 
repopulate the leukemia. Thus, a maneuver revealing therapeutic activity in this model likely 
targets not only the bulk of the leukemic blasts, but also leukemic stem cells, the most 
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relevant target for novel therapeutic approaches in this disease. However, the adequacy of 
the in vivo model to predict the clinical activity of donor CD19-redirected T cells against 
refractory leukemias is still limited. Firstly, there is a narrow experimental window, since 
engraftment of an individual donor´s leukemic cells varies greatly. Even the use of novel, 
more robust mouse models for human leukemia engraftment, e.g. NOD/LtSz-scid IL2Rγc 
null (NSG) mice, can not easily overcome this limitation. Secondly, the model is not easily 
suitable for larger-size experiments, and miscalculated cell load can either lead to no 
engraftment at all or rapid engraftment with no therapeutic activity (one experiment each with 
different donors, details not shown). Thirdly, the immuno-deficient, murine bone marrow 
environment does not allow to study T-cell survival, persistence and memory function, which 
have emerged from the first clinical studies as major issues for advancing cellular 
immunotherapies. Finally, the model can not ultimately address the question whether CD19 
is the appropriate target to eradicate and cure this leukemia. A recent study has 
demonstrated that a variety of leukemic cells at different stages of maturation, including both 
CD19+ and CD19-negative cells, can propagate the leukemia in NOD/scid mice(6). Even 
though the failure of leukemic BM to engraft in the presence of CD19ζ T cells and upon 
retransplantation into untreated mice indicates efficient control of leukemia through 
controlling CD19-positive leukemic precursors, subsequent reemergence of the leukemic 
clone from persisting CD19-negative leukemia initiating cells can not be excluded. 
Addressing these questions will require clinical efficacy studies of CD19-specific T cells in 
leukemia patients, the first of which are currently being launched. For efficient translation of 
this strategy into clinical leukemia treatment, optimal integration into current standard 
chemotherapy and allogeneic HSCT will be paramount. This could include MRD-based 
timing of immune intervention, measures to overcome the immunosuppressive 
microenvironment of the leukemic bone marrow, e.g. by depletion of regulatory T cells prior 
to adoptive T-cell transfer, and vaccination-based approaches to prolong effector cell 
persistence.  
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Supplemental Information accompanies the paper on the Leukemia website 
(http://www.nature.com/leu) 
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Figure legends 
Figure 1. CAR transduced EBV-CTLs exert powerful in vitro cytolytic responses 
against CD19-expressing cell lines and primary leukemia targets. (A) CAR surface 
expression on transduced CTLs was determined by flow cytometry after staining with 
biotinylated goat anti-mouse antibody specific for IgG F(ab’)2 fragment and secondary 
phycoerythrin (PE)-labeled streptavidin antibody. Shown is one representative example of 
nine. (B) Cell surface expression of CD45RO and CCR7 on CAR-transduced EBV-CTLs by 
flow cytometry. Representative example of three. (C). Specific cytolysis of CD19+ GD2-
negative (REH) and CD19-negative, GD2-negative (ML-2) leukemia cells and CD19+ primary 
leukemia cells obtained from patient BM by CD19ζ (left panel) and 14.G2aζ (right panel) 
CAR transduced T cells in a 51Cr-release assay. Shown is one representative experiment 
each of five. The leukemic cells are from the same patient as in the in vivo experiment in 
Figure 2. (D) Specific cytolysis (by 51Cr release) of primary leukemia cells obtained from 5 
patients and of CD19+ SupB15 leukemia cells by CD19ζ-transduced and control (14.G2aζ- 
or non-transduced) EBV-CTLs at a 20:1 effector-to-target ratio. Data represent the means 
and standard deviations of triplicate wells of one experiment for each primary leukemia 
target. For SupB15, means and standard deviations derive from seven individual 
experiments. (E) Specific interferon-γ secretion by CD19ζ transduced EBV-CTLs by 
ELISPOT analysis. 2x103 CTLs were incubated for 16 hours in the presence of medium 
(negative control), or coincubated with 1x105 CD19+ SupB15 cells, primary leukemia cells, or 
autologous LCLs (positive control).  
Figure 2. CD19ζ transduced EBV-CTLs prevent engraftment of human primary 
leukemia cells in NOD/scid mice and extend survival. 1x104 leukemic cells per mouse 
from mice primary engrafted with BM from a patient diagnosed with an MLL-rearranged 
CD19+ ALL were transferred into a further cohort of NOD/scid mice by intrafemoral injection. 
Four doses of 5x106 EBV-CTL, transduced with either CD19ζ (n = 8) or 14.G2aζ (n = 5) 
were administered via tail vein injection on days 1, 4, 8, and 11. IL-2 (500 IU/mouse) was 
administered twice-weekly. (A) Sequential murine BM aspirates were analyzed for human 
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leukemia engraftment by flow cytometry starting 3 weeks after transplantation, showing lack 
of engraftment in a mouse after transfer of CD19ζ transduced CTLs (upper panel), and 
human leukemia engraftment in a mouse receiving 14.G2aζ transduced control CTLs. (B) 
Leukemia-free (left panel) and overall (right panel) survival in the entire experimental cohort. 
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